CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向磷脂酰肌醇蛋白聚糖 3 的肝细胞癌联合治疗策略：一篇综合性综述

Combination therapy strategies targeting glypican-3 in hepatocellular carcinoma: A comprehensive review.

分子受体 NKBB 增强 GPC3 CAR-T 细胞的持久性和抗肝细胞癌活性

The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells.

靶向 Lin28 轴增强 glypican-3-CAR-T 细胞对肝肿瘤起始细胞群的疗效

Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.

新型靶向磷脂酰肌醇蛋白聚糖 3（GPC3）的 CAR-T 细胞疗法 JWATM204 治疗晚期肝细胞癌的安全性和疗效：一项 I 期剂量递增研究

Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalatio

JWATM204 在晚期 GPC3 阳性 HCC 患者中表现出良好的安全性特征，并显示出初步的抗肿瘤活性。外周血 NK 细胞水平以及肿瘤 CRP 和 CYP2E1 表达可能作为治疗反应的潜在生物标志物，为进一步优化 HCC 的 CAR-T 细胞治疗提供了依据。

肝细胞癌嵌合抗原受体（CAR）T 细胞治疗近期进展综述

A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.

可溶性程序性死亡配体-1 对肝细胞癌中靶向 GPC3 的嵌合抗原受体 NK 细胞的免疫抑制效应

Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatoce

GPC3 CAR-iNKT 细胞在肝细胞癌小鼠模型中的抗肿瘤作用

Anti-tumor effects of GPC3 CAR-iNKT cells in murine models of hepatocellular carcinoma.

新型 LAG3 中和抗体通过双重抑制 MHC-II 与 FGL1 配体结合改善肿瘤免疫治疗

A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.

DAP10 整合入 CAR-T 细胞通过利用内源性 NKG2D 增强对异质性肿瘤的杀伤

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.